BRCA2 and cancer: The aforementioned study indicated that the incorporation of PRSs into risk prediction models can improve the calculation of personalized risk estimates for individuals carrying mutations in BRCA1 and BRCA2; in addition, it can guide clinical decisions regarding the management of cancer risk13.